Back to companies

Zealand Pharma AS: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Zealand Pharma AS (Zealand Pharma) is a biotechnology company that discovers and develops peptide-based medicines. The company's pipeline products include Dapiglutide, Petrelintide, ZP6590, ZP9830, ZP10068, Survodutide, Dasiglucagon, Glepaglutide and Dasiglucagon. Its products useful for the indication of obesity, metabolic dysfunction-associated steatohepatitis (MASH), congenital hyperinsulinism, chronic inflammation, short bowel syndrome and type 1 diabetes. Zealand Pharma utilizes validated peptide platform for the discovery, design, and development of their peptide-based medicines. It works in collaboration with DEKA Research & Development Corporation, Boehringer Ingelheim and Alexion Pharmaceuticals. The company operates in Denmark and the US. Zealand Pharma is headquartered in Soeborg, Denmark.

 Gain a 360-degree view of Zealand Pharma AS and make more informed decisions for your business Gain a 360-degree view of Zealand Pharma AS and make more informed decisions for your business Register your interest
Headquarters Denmark
Address Sydmarken 11, Soeborg, 2860
Website www.zealandpharma.com
Telephone 45 88773600
No of Employees 544
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ZEAL (CPH)
Revenue (2024) $1.4B 14598.9% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 698.3% (2024 vs 2023)
Market Cap* $3.5B
Net Profit Margin (2024) XYZ 104.1% (2024 vs 2023)
* As of and is in US$
View Zealand Pharma AS financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Zealand Pharma AS premium industry data and analytics

130+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Zealand Pharma AS’s relevant decision makers and contact details.

90+

Catalyst Calendar

Proactively evaluate Zealand Pharma AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Clinical Trials

Determine Zealand Pharma AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Pipeline Drugs

Identify which of Zealand Pharma AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

13+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Zealand Pharma AS’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products
Pipeline:
Glepaglutide: Short Bowel Syndrome
ZP6590: Obesity
XYZ
XYZ
XYZ
Understand Zealand Pharma AS portfolio and identify potential areas for collaboration Understand Zealand Pharma AS portfolio and identify potential areas for collaboration Register your interest

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2026 Corporate Changes/Expansions In March, the company established a US research hub in Cambridge, Massachusetts.
2026 Contracts/Agreements In January, the company partnered with DCAI to use the Gefion AI supercomputer to accelerate drug discovery and advance its Metabolic Frontier 2030 strategy.
2025 Contracts/Agreements In December, the company entered into a partnership with OTR Therapeutics to develop novel therapeutics for metabolic diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Register your interest
Image for loader

Competitor Comparison

Key Parameters Zealand Pharma AS Genmab AS Bavarian Nordic AS Ascendis Pharma AS Forward Pharma AS
Headquarters Denmark Denmark Denmark Denmark Denmark
City Soeborg Valby Hellerup Hellerup Hellerup
No. of Employees 544 2,682 1,605 1,189 4
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Martin Nicklasson Chairman Executive Board 2015 71
Kirsten A. Drejer Vice Chairman Executive Board 2018 70
Adam Steensberg President; Chief Executive Officer Senior Management 2022 52
Henriette Wennicke Chief Financial Officer; Executive Vice President Senior Management 2022 42
Ivan Moller Chief Operating Officer; Executive Vice President Senior Management 2018 54
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Zealand Pharma AS key executives to enhance your sales strategy Gain insight into Zealand Pharma AS key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?